Novartis & Gsk Collaborate To Support Scientific Research Into Genetic Diversity In Africa

Novartis And Gsk Announced The Launch Of A Collaboration To Support High-Quality Scientific Research Investigating The Link Between Genetic Diversity Across Different Regions In Africa And Its Potential Impact On Response To Drug Therapeutics.The Project Africa Genomic Research Approach For Diversity And Optimizing Therapeutics (Gradient), With A Combined Funding Commitment Of Gbp 2.8 Million (Us$ 3.6 Million) Over Five Years, Calls On African Researchers To Submit Robust Research Proposals On The Relevance Of African Genetic Diversity To The Treatment Of Malaria And Tuberculosis (Tb).Lutz Hegemann, M.D., Chief Operating Officer For Global Health At Novartis Said: &Ldquo;Novartis Has A Long-Standing Commitment To Improving And Extending The Lives Of Patients Around The World. Our Efforts Include Seeking Innovative Ways To Improve The Standard Of Care Where Possible. This Is Why We Are Excited By This Important Collaboration On Scientific Research On Genetic Diversity In Africa. It Has The Potential To Improve The Efficacy And Tolerability Of Current And Future Medicines, Starting With Two Of The Most Deadly Diseases, Malaria And Tuberculosis. In Alignment With Our Ongoing Efforts To Strengthen Scientific Capabilities In Lower-Resource Settings, This Project Also Provides Opportunities For Training Young African Scientists In The Use Of Advanced Research Methodologies And Mentoring On Drug Development.&Rdquo;Pauline Williams, Senior Vice President Global Health Pharma At Gsk Said: &Ldquo;At Gsk, Human Genetics Is A Core Pillar Of Our R&Amp;D Strategy. Genetic Diversity Is Greater In Africa Than In Any Other Continental Population Resulting In Some African Patients Having Varying Response To Treatments. We Are Excited To Launch Project Africa Gradient Which Aims To Catalyze The Best Science In The Continent To Optimize Treatment Responses For Malaria And Tuberculosis, Two Infectious Diseases That Disproportionately Affect African Populations.&Rdquo;Prof. Glenda Gray, Samrc President And Ceo, Said: &Ldquo;It Is Exciting To See More And More Global Partners Taking Interest In The Challenges Of Africa. We Are Delighted That Partners Are Now Seeking To Address The Challenges Of Africa By Their Quest To Understand The Fundamental Differences Between Genetics Of Africa And The Rest Of The World.&Rdquo;As A First Step, Researchers Based At Universities, Science Councils And Other Public Research Organizations Across Africa Are Invited To Express Their &Lsquo;Intent To Submit&Rsquo; Through The Samrc Website. Final Award Recipients Are Expected To Be Announced By End Of 2021.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!